title: Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model.
abstract: OBJECTIVE
  To determine the reliable perfusion parameters in dynamic contrast-enhanced MRI (DCE-MRI) for the monitoring antiangiogenic treatment in mice.
  
  
  METHODS
  Mice, with U-118 MG tumor, were treated with either saline (n = 3) or antiangiogenic agent (sunitinib, n = 8). Before (day 0) and after (days 2, 8, 15, 25) treatment, DCE examinations using correlations of perfusion parameters (Kep, Kel, and A(H) from two compartment model; time to peak, initial slope and % enhancement from time-intensity curve analysis) were evaluated.
  
  
  RESULTS
  Tumor growth rate was found to be 129% ± 28 in control group, -33% ± 11 in four mice with sunitinib-treatment (tumor regression) and 47% ± 15 in four with sunitinib-treatment (growth retardation). Kep (r = 0.80) and initial slope (r = 0.84) showed strong positive correlation to the initial tumor volume (p < 0.05). In control mice, tumor regression group and growth retardation group animals, Kep (r : 0.75, 0.78, 0.81, 0.69) and initial slope (r : 0.79, 0.65, 0.67, 0.84) showed significant correlation with tumor volume (p < 0.01). In four mice with tumor re-growth, Kep and initial slope increased 20% or greater at earlier (n = 2) than or same periods (n = 2) to when the tumor started to re-grow with 20% or greater growth rate.
  
  
  CONCLUSIONS
  Kep and initial slope may a reliable parameters for monitoring the response of antiangiogenic treatment.
authors.affiliation: Division of Magnetic Resonance, Korea Basic Science Institute, Cheongwon 363-883, Korea.
authors.forename: Youngkyu
authors.initials: Y
authors.lastname: Song
authors.forename: Gyunggoo
authors.initials: G
authors.lastname: Cho
authors.forename: Ji-Yeon
authors.initials: JY
authors.lastname: Suh
authors.forename: Chang Kyung
authors.initials: CK
authors.lastname: Lee
authors.forename: Young Ro
authors.initials: YR
authors.lastname: Kim
authors.forename: Yoon Jae
authors.initials: YJ
authors.lastname: Kim
authors.forename: Jeong Kon
authors.initials: JK
authors.lastname: Kim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D003287:Contrast Media; D005260:Female; D064593:Heterografts; D007211:Indoles / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D011758:Pyrroles / Q000627:therapeutic use*; D015203:Reproducibility of Results; D000077210:Sunitinib; D047368:Tumor Burden
chemical_list: D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: Angiogenesis; Dynamic contrast enhanced MR; Tumor perfusion; Two compartment model
references.citation: Korean J Radiol. 2011 Nov-Dec;12(6):722-30
references.pmid: 22043155
references.citation: Radiology. 2005 Apr;235(1):65-72
references.pmid: 15731376
references.citation: Mol Cancer Ther. 2006 May;5(5):1280-9
references.pmid: 16731761
references.citation: Mol Cancer Ther. 2006 Aug;5(8):1950-7
references.pmid: 16928815
references.citation: Korean J Radiol. 2009 Nov-Dec;10(6):535-51
references.pmid: 19885309
references.citation: Radiother Oncol. 2000 Oct;57(1):53-9
references.pmid: 11033189
references.citation: Cancer Res. 2005 Aug 15;65(16):7041-4
references.pmid: 16103049
references.citation: NMR Biomed. 2002 Apr;15(2):89-98
references.pmid: 11870904
references.citation: N Engl J Med. 2008 May 8;358(19):2039-49
references.pmid: 18463380
references.citation: Oncologist. 2001;6(6):517-37
references.pmid: 11743214
references.citation: Eur J Radiol. 2009 Sep;71(3):498-505
references.pmid: 18572340
references.citation: Korean J Radiol. 2012 Jul-Aug;13(4):371-90
references.pmid: 22778559
references.citation: J Magn Reson Imaging. 1999 Sep;10(3):223-32
references.pmid: 10508281
references.citation: J Magn Reson Imaging. 1997 May-Jun;7(3):461-4
references.pmid: 9170027
references.citation: J Magn Reson Imaging. 2002 Mar;15(3):233-40
references.pmid: 11891967
references.citation: J Magn Reson Imaging. 1999 Sep;10(3):260-6
references.pmid: 10508285
references.citation: Magn Reson Med. 1994 Nov;32(5):646-51
references.pmid: 7808266
references.citation: Magn Reson Med. 1995 Apr;33(4):506-14
references.pmid: 7776881
references.citation: Radiology. 2003 Jun;227(3):617-22
references.pmid: 12773666
references.citation: J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8
references.pmid: 2061479
references.citation: J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101
references.pmid: 9039598
references.citation: Clin Pharmacol Ther. 2012 Jul;92(1):118-24
references.pmid: 22588603
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Br J Cancer. 2006 May 22;94(10):1420-7
references.pmid: 16670720
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s
references.pmid: 17255308